NASDAQ · PBM
Healthcare · Biotechnology
$4.17
Up+$0.05 (+1.09%)
Updated Oct 24, 2026, 12:10 PM
SID Score
3.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PBM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 23, 2026
PBM closed at $4.17 after 21 trading sessions, down 25.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 23, 2026 | $4.11 | $4.29 | $4.06 | $4.165 | 13.18K |
| Oct 22, 2026 | $4.39 | $4.7679 | $4.12 | $4.12 | 57.05K |
| Oct 21, 2026 | $4.36 | $4.72 | $4.36 | $4.52 | 39.29K |
| Oct 20, 2026 | $4.09 | $4.5099 | $4.06 | $4.24 | 44.47K |
| Oct 19, 2026 | $4.09 | $4.275 | $4.08 | $4.12 | 34.53K |
| Oct 16, 2026 | $4.34 | $4.53 | $4.16 | $4.22 | 26.54K |
| Oct 15, 2026 | $4.09 | $4.44 | $4.09 | $4.32 | 16.95K |
| Oct 14, 2026 | $4.53 | $4.8206 | $4.10 | $4.13 | 68.41K |
| Oct 13, 2026 | $4.70 | $4.79 | $4.55 | $4.55 | 35.88K |
| Oct 12, 2026 | $4.88 | $5.0407 | $4.73 | $4.74 | 25.43K |
| Oct 9, 2026 | $5.205 | $5.205 | $4.93 | $4.97 | 23.96K |
| Oct 8, 2026 | $4.88 | $5.22 | $4.86 | $5.12 | 67.19K |
| Oct 7, 2026 | $4.93 | $5.10 | $4.835 | $4.88 | 16.93K |
| Oct 6, 2026 | $5.08 | $5.30 | $4.8901 | $5.02 | 51.19K |
| Oct 5, 2026 | $5.27 | $5.56 | $4.96 | $5.08 | 145.55K |
| Oct 2, 2026 | $5.52 | $5.6325 | $5.12 | $5.16 | 75.15K |
| Oct 1, 2026 | $5.42 | $5.70 | $5.40 | $5.48 | 14.96K |
| Sep 30, 2026 | $5.43 | $5.7213 | $5.38 | $5.46 | 17.93K |
| Sep 29, 2026 | $5.68 | $5.7304 | $5.41 | $5.43 | 27.74K |
| Sep 28, 2026 | $5.59 | $5.8199 | $5.51 | $5.665 | 48.33K |
| Sep 25, 2026 | $5.81 | $5.96 | $5.41 | $5.56 | 110.56K |
The latest Smart Investors Daily articles mentioning PBM.
Company
Market Activity
Research & News
PBM research
Company profile and research snapshot.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Mar 3, 2026
Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced the
Yahoo · Feb 11, 2026
NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company") today announced that it has entered into a settlement agreement to resolve a direct shareholder claim made by KAOS Capital Ltd ("KAOS"). The claim, originally made on January 14, 2026, and amplified on January 26, 2026, alleged, among other things, improper and oppressive actions on the part of the Company against KAOS, resulting in KAOS suffering alleged damages (the "KAOS Alleg
Yahoo · Jan 15, 2026
NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), today announced the effective date of its 1-for-6.25 share consolidation (reverse stock split) of the Company's issued and outstanding common shares. At a Special Meeting of Stockholders held on April 16, 2025, shareholders approved a special resolution authorizing the Board of Directors, at any time prior to the next annual meeting of shareholders, to implement a share consolid
Yahoo · Jan 12, 2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet mental health needs, today announced that its Board of Directors (the “Board”) has approved its 2026 Financial Strategy and Capital Management Framework, which includes the authorization of a share repurchase program that the management may undertake in value generation conditions. T
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PBM.
